Short answer
CATALYST PHARMACEUTICALS, INC. (CPRX) filed an 8-K current report with the SEC on May 7, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Angelini Pharma acquisition at $31.50 cash per share, taking Catalyst private as a wholly owned subsidiary.
CATALYST PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Angelini Pharma acquisition at $31.50 cash per share, taking Catalyst private as a wholly owned subsidiary
- Closing targeted for Q3 2026, subject to shareholder approval, HSR clearance, and other customary conditions
- No financing condition, with Parent funding the transaction through cash on hand and debt financing
- $155.5M termination fee creates significant deterrence against competing bids or deal failure under specified circumstances
- Directors and executive officers committed their shares to support the merger and oppose competing proposals
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Board-approved amendment to Article VIII, Section 8.1 of Catalyst Pharmaceuticals’ bylaws
- Forum Selection Amendment governs where certain shareholder or corporate litigation may be filed
- Exhibit 3.1 contains the operative language and determines the amendment’s scope
- Shareholder litigation venue options may narrow, affecting future legal strategy and costs
Item 7.01 · Regulation FD Disclosure
- Catalyst Pharmaceuticals and Parent announced execution of a merger agreement
- Exhibit 99.1 contains the transaction announcement and substantive deal details
- Disclosure furnished under Regulation FD, limiting its status as a filed report
Item 8.01 · Other Events
- FIRDAPSE generic entry by Hetero deferred until January 2035, subject to FDA approval and customary settlement exceptions
- Settlement terminates Hetero patent litigation against Catalyst and licensor SERB in New Jersey federal court
- Extended exclusivity supports long-term FIRDAPSE revenue protection and reduces near-term generic pricing pressure
- Settlement Agreement requires review by the Federal Trade Commission and Department of Justice
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CATALYST PHARMACEUTICALS, INC. 8-K filings
Get the next CPRX 8-K as it lands
Follow CPRX for push alerts, or ask the research agent what this filing means.